IP Library Granted Patent US 9,796,978
Granted Patent B1
US 9,796,978 · App. 15/652,219 · Granted Oct 24, 2017

Oligonucleotide compositions with enhanced efficiency

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,796,978
App. No.
15/652,219
Granted
Oct 24, 2017
Kind
B1
Abstract

The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.

Claims (38)

1. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three or four different double-stranded oligonucleotides,

wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,

each double-stranded oligonucleotide consists of two separate strands,

each strand is between 20 and 30 nucleomonomers in length,

wherein the combination is capable of RNA interference (RNAi), and

wherein at least one of the oligonucleotides comprises at least one modified internucleoside linkage or

wherein at least one of the oligonucleotides comprises at least one modified sugar moiety.

2. The composition of claim 1 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety.

3. The composition of claim 2 wherein at least one nucleomonomer of at least one strand comprises a pyrimidine and the pyrimidine is thymine or 5-methylcytosine.

4. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

5. The composition of claim 1 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

6. The composition of claim 2 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

7. The composition of claim 3 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

8. The composition of claim 1 , wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

9. The composition of claim 1 , wherein the target gene is a mammalian gene.

10. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of two different double-stranded oligonucleotides,

wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,

each double-stranded oligonucleotide consists of two separate strands,

each strand is between 20 and 30 nucleomonomers in length,

wherein the combination is capable of RNA interference (RNAi), and

wherein at least one of the oligonucleotides comprises at least one modified internucleoside linkage or

wherein at least one of the oligonucleotides comprises at least one modified sugar moiety.

11. The composition of claim 10 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety.

12. The composition of claim 11 wherein at least one nucleomonomer of at least one strand comprises a pyrimidine and the pyrimidine is thymine or 5-methylcytosine.

13. The composition of claim 10 , further comprising a pharmaceutically acceptable carrier.

14. The composition of claim 10 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

15. The composition of claim 11 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

16. The composition of claim 12 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

17. The composition of claim 10 , wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

18. The composition of claim 10 , wherein the target gene is a mammalian gene.

19. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of five, six, seven or eight different double-stranded oligonucleotides,

wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,

each double-stranded oligonucleotide consists of two separate strands,

each strand is between 20 and 30 nucleomonomers in length,

wherein the combination is capable of RNA interference (RNAi), and

wherein at least one of the oligonucleotides comprises at least one modified internucleoside linkage or

wherein at least one of the oligonucleotides comprises at least one modified sugar moiety.

20. The composition of claim 19 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: WOOLF, TOD; TAYLOR, MARGARET
To: SEQUITUR, INC.
Reel/Frame 043345/0783 →
MERGER Recorded Aug 21, 2017
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 043346/0008 →
MERGER Recorded Aug 21, 2017
From: SEQUITUR, INC.
To: INVITROGEN CORPORATION
Reel/Frame 043612/0458 →